Pfizer Launches Rimegepant for Migraine Treatment

1 Minute Read Listen to Article
Share:    

Nov 17, 2025 14:38

x
Pfizer introduces Rimegepant ODT in India for migraine treatment, offering rapid, sustained relief without overuse headache risk.
Pfizer Launches Rimegepant for Migraine Treatment
New Delhi, Nov 17 (PTI) Drug maker Pfizer on Monday said it has launched a new medication for migraine treatment.

The company has introduced Rimegepant ODT in India for adults with a previous insufficient response to triptan, the usual drugs for treating migraine.

The new medication delivers rapid and sustained pain relief lasting up to 48 hours post-treatment, while not associated with the risk of medication overuse headaches, Pfizer Ltd said in a statement.


Rimegepant will be available in a 75 mg orally disintegrating tablet (ODT) form, designed for convenient administration without the need for water, it added.

"We believe this treatment will help people with migraine manage pain more effectively and reclaim productive days sooner than with currently available options," Pfizer MD Meenakshi Nevatia stated.

Migraine poses a significant challenge in India, affecting around 213 million people annually, with an estimated 17.3 days of productivity loss observed per year.
Share:    

TODAY'S MOST TRADED COMPANIES

  • Company Name
  • Price
  • Volume

See More >

Moneywiz Live!

Home

Market News

Latest News

International Markets

Economy

Industries

Mutual Fund News

IPO News

Search News

My Portfolio

My Watchlist

Gainers

Losers

Sectors

Indices

Forex

Mutual Funds

Feedback